User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.

Primary tabs

Frey, K A Koeppe, R A Kilbourn, M R Vander Borght, Thierry [UCL] Albin, R L Kuhl, D E

We present development and human application of a method for determining the regional cerebral density of the type 2 vesicular monoamine transporter (VMAT2) using positron emission tomography (PET) and [11C]dihydrotetrabenazine (DTBZ). Previous animal studies indicate striatal VMAT2 density is linearly related to the integrity of substantia nigra dopamine neurons and is not subject to drug- or lesion-compensatory regulation. In the present studies, kinetic compartmental modeling was employed to estimate blood-brain [11C]DTBZ transport (K1) and VMAT2 binding site density (tissue-to-plasma DTBZ distribution volume, DV) from the cerebral and plasma DTBZ time courses after intravenous tracer injection. In controls, we found reductions of putamen DTBZ DVwith advancing age, corresponding to losses of 0.77% per year in specific VMAT2 binding. Parkinson's disease (PD) patients had reduction in specific DTBZ DV in the putamen (-61%) and in the caudate nucleus (-43%). There was no overlap of lowest specific putamen DTBZ DV between individual elderly controls and PD patients. The present results indicate the suitability of [11C]DTBZ PET for objective quantification of nigrostriatal integrity, including evaluation of PD progression and its possible therapeutic modification.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 1996
Language Anglais
Journal information "Annals of neurology" - Vol. 40, no.6, p. 873-84 (1996)
Peer reviewed yes
issn 0364-5134
Publication status Publié
Affiliation UCL - (MGD) Service de médecine nucléaire
MESH Subject Adult ; Humans ; Male ; Membrane Glycoproteins ; Membrane Transport Proteins ; Middle Aged ; Neuropeptides ; Parkinson Disease ; Presynaptic Terminals ; Rats ; Tetrabenazine ; Aged ; Tomography, Emission-Computed ; Vesicular Biogenic Amine Transport Proteins ; Vesicular Monoamine Transport Proteins ; Aging ; Animals ; Biological Markers ; Biological Transport ; Blood-Brain Barrier ; Cerebral Cortex ; Female
Links
  1. Hornykiewicz, Pharmacol Rev, 18, 925 (1966)
  2. Kish, N Engl J Med, 318, 876 (1988)
  3. The neuropathology and neurochemistry of multiple system atrophy. In: eds. Autonomic failure: a textbook of clinical disorders of the autonomic nervous system. 3rd ed. Oxford: Oxford University Press, 1992: 564-585
  4. STEELE JOHN C., Progressive Supranuclear Palsy : A Heterogeneous Degeneration Involving the Brain Stem, Basal Ganglia and Cerebellum With Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia and Dementia, 10.1001/archneur.1964.00460160003001
  5. Tanner, Neurology, 40, 17 (1990)
  6. Rajput A. H., Environmental Causation of Parkinson's Disease, 10.1001/archneur.1993.00540060081022
  7. Jenner P., Schapira A. H. V., Marsden C. D., New insights into the cause of Parkinson's disease, 10.1212/wnl.42.12.2241
  8. Fahn, Ann Neurol, 32, 804 (1992)
  9. Sian, Ann Neurol, 36, 348 (1994)
  10. The Parkinson Study Group, N Engl J Med, 328, 176 (1993)
  11. Przedborski, Ann Neurol, 34, 715 (1993)
  12. Garnett, Nature, 305, 137 (1983)
  13. Leenders K. L., Salmon E. P., Tyrrell P., Perani D., Brooks D. J., Sager H., Jones T., Marsden C. D., Frackowiak R. S. J., The Nigrostriatal Dopaminergic System Assessed In Vivo by Positron Emission Tomography in Healthy Volunteer Subjects and Patients With Parkinson's Disease, 10.1001/archneur.1990.00530120034007
  14. Frost, Ann Neurol, 34, 423 (1993)
  15. van Dyck, J Nucl Med, 36, 1175 (1995)
  16. Vander Borght, J Nucl Med, 36, 2252 (1995)
  17. Vander Borghr, Eur J Pharmacol, 294, 577 (1996)
  18. Naudon, Neurosci Lett, 173, 1 (1994)
  19. Vander Borght, Neuroscience, 68, 955 (1995)
  20. et al. Decreased striatal monoaminergic terminals in OPCA and MSA demonstrated with PET. Ann Neurol 1996 (In press)
  21. Hoehn, Neurology, 17, 427 (1967)
  22. DaSilva, Appl Radiat Isot, 44, 673 (1993)
  23. Kilbourn, Eur J Pharmacol, 278, 249 (1995)
  24. Frey K. A., Koeppe R. A., Mulholland G. K., Jewett D., Hichwa R., Ehrenkaufer R. L. E., Carey J. E., Wieland D. M., Kuhl D. E., Agranoff B. W., In vivo Muscarinic Cholingeric Receptor Imaging in Human Brain with [11C]Scopolamine and Positron Emission Tomography, 10.1038/jcbfm.1992.18
  25. Frey, Ann Neurol, 30, 663 (1991)
  26. Koeppe Robert A., Frey Kirk A., Mulholland G. Keith, Kilbourn Michael R., Buck Alfred, Lee Kien S., Kuhl David E., [11C]Tropanyl Benzilate—Binding to Muscarinic Cholinergic Receptors: Methodology and Kinetic Modeling Alternatives, 10.1038/jcbfm.1994.13
  27. Scherman, J Neurochem, 50, 1131 (1988)
  28. Pearson, Neuropharmacology, 27, 717 (1988)
  29. Erickson, J Neurochem, 61, 2314 (1993)
  30. Kish S. J., Robitaille Y., El-Awar M., Clark B., Schut L., Ball M. J., Young L. T., Currier R., Shannak K., Striatal monoamine neurotransmitters and metabolites in dominantly inherited olivopontocerebellar atrophy, 10.1212/wnl.42.8.1573
  31. Effects of dopaminergic drug treatments on in vivo radioligand binding to brain monoamine transporters. Nucl Med Biol 1996 (In press)
  32. Gjedde, Proc Natl Acad Sci USA, 88, 2721 (1991)
  33. Hadjiconstantinou, J Neurochem, 60, 2175 (1993)
  34. Young, J Neurochem, 60, 2331 (1993)
  35. Zhu, Eur J Pharmacol, 238, 157 (1993)
  36. Cumming, J Neurochem, 65, 1381 (1995)
  37. Weiner, Eur J Pharmacol, 163, 191 (1989)
  38. Ikegami, Peptides, 11, 145 (1990)
  39. Meietgerd, J Neurochem, 63, 1277 (1994)
  40. Wilson, J Neurosci, 14, 2966 (1994)
  41. Kilbourn, J Neurochem, 60, 2315 (1993)
  42. Kilbourn, J Cereb Blood Flow Metab, 15, s650 (1995)
  43. McGeer P. L., McGeer E. G., Suzuki J. S., Aging and Extrapyramidal Function, 10.1001/archneur.1977.00500130053010
  44. Fearnley, Brain, 114, 2283 (1991)
  45. Scherman, Ann Neurol, 26, 551 (1989)
  46. Zelnik, Eur J Pharmacol, 126, 175 (1986)
  47. De Keyser, Ann Neurol, 27, 157 (1990)
  48. Volkow, Ann Neurol, 36, 237 (1994)
  49. Martin, Ann Neurol, 26, 535 (1989)
  50. Cordes, Ann Neurol, 36, 667 (1994)
  51. Sawle, Ann Neurol, 28, 799 (1990)
  52. Eidelberg D., Takikawa S., Dhawan V., Chaly T., Robeson W., Dahl R., Margouleff D., Moeller J. R., Patlak C. S., Fahn S., Striatal 18F-DOPA Uptake: Absence of an Aging Effect, 10.1038/jcbfm.1993.110
  53. Kish, Ann Neurol, 38, 260 (1995)
  54. Lehéricy, Brain Res, 659, 1 (1994)
  55. Bernheimer, J Neurol Sci, 20, 415 (1973)
  56. Niznik, J Neurochem, 56, 192 (1991)
  57. Kaufman, Synapse, 9, 43 (1991)
  58. Chinaglia, Neuroscience, 49, 317 (1992)
  59. Seibyl, Ann Neurol, 38, 589 (1995)
  60. Sawle Guy V., Separating Parkinson's Disease From Normality : Discriminant Function Analysis of Fluorodopa F 18 Positron Emission Tomography Data, 10.1001/archneur.1994.00540150027011
  61. Hefti, Brain Res, 195, 123 (1980)
  62. Zhong, Mov Disord, 10, 10 (1995)
  63. Gjedde, J Neurochem, 61, 1538 (1993)
  64. Marquardt, J Soc Indust Appl Math, 11, 431 (1963)
  65. Alpert N. M., Eriksson L., Chang J. Y., Bergstrom M., Litton J. E., Correia J. A., Bohm C., Ackerman R. H., Taveras J. M., Strategy for the Measurement of Regional Cerebral Blood Flow Using Short-Lived Tracers and Emission Tomography, 10.1038/jcbfm.1984.4
  66. et al. Kinetic evaluation of [11C]dihydrotetrabenazine by dynamic PET: measurement of the vesicular monoamine transporter. J Cereb Blood Flow Metab 1996 (In press)
Bibliographic reference Frey, K A ; Koeppe, R A ; Kilbourn, M R ; Vander Borght, Thierry ; Albin, R L ; et. al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.. In: Annals of neurology, Vol. 40, no.6, p. 873-84 (1996)
Permanent URL http://hdl.handle.net/2078.1/123341